HIV prophylaxis expensive and sometimes difficult to obtain

Silversides, Ann
November 2006
CMAJ: Canadian Medical Association Journal;11/21/2006, Vol. 175 Issue 11, p1359
Academic Journal
This article reports on the concerns over post-exposure prophylaxis (PEP) for HIV infections in Canada in 2006. The government is facing a problem about the cost effectiveness of PEP for HIV. Some doctors are also concern with the absence of real consensus in the area. In addition, the article mentions policy and service delivery guidance for PEP that will be released by the World Health Organization.


Related Articles

  • Letter from the Editor.  // Eastern Mediterranean Health Journal;Aug2010, Vol. 16 Issue 8, p811 

    The author discusses an increase in international mobilization to fight HIV which has been seen since the establishment of the Millennium Development Goals. A discussion of factors that limit the mobilization efforts is presented. In the article the author offers opinions on the mobilization...

  • Implications of the new WHO guidelines on HIV and infant feeding for child survival in South Africa. Doherty, Tanya; Sanders, David; Goga, Ameena; Jackson, Debra // Bulletin of the World Health Organization;Jan2011, Vol. 89 Issue 1, p62 

    Abstract The World Health Organization released revised principles and recommendations for HIV and infant feeding in November 2009. The recommendations are based on programmatic evidence and research studies that have accumulated over the past few years within African countries. This document...

  • Country adaptation of the 2010 World Health Organization recommendations for the prevention of mother-to-child transmission of HIV. Ghanotakis, Elena; Miller, Lior; Spensley, Allison // Bulletin of the World Health Organization;Dec2012, Vol. 90 Issue 12, p921 

    The World Health Organization (WHO) revised its global recommendations on treating pregnant women infected with the human immunodeficiency virus (HIV) with antiretrovirals and preventing mother-to-child transmission (PMTCT) of HIV. Initial draft recommendations issued in November 2009 were...

  • Buprenorphine Use: The International Experience. Carrieri, Maria Patrizia; Amass, Leslie; Lucas, Gregory M.; Vlahov, David; Wodak, Alex; Woody, George E. // Clinical Infectious Diseases;12/15/2006 Supplement, Vol. 43, pS197 

    The confluence of the heroin injection epidemic and the human immunodeficiency virus (HIV) infection epidemic has increased the call for expanded access to effective treatments for both conditions. Buprenorphine and methadone are now listed on the World Health Organization's Model Essential...

  • Strengthening adherence to Anti Retroviral Therapy (ART) monitoring and support: operation research to identify barriers and facilitators in Nepal. Bam, Kiran; Rajbhandari, Rajesh M.; Karmacharya, Dibesh B.; Dixit, Sameer M. // BMC Health Services Research;2015, Vol. 15 Issue 1, p1 

    Background: Anti Retroviral Therapy (ART) is the cornerstone for comprehensive health sector response to Human Immunodeficiency Virus (HIV) treatment, care and support. Adherence of at least 95% is needed to keep HIV under control, as per World Health Organization (WHO) guidelines. This study...

  • Earlier Initiation of Antiretroviral Therapy Should Be Highest Priority for Expansion of HIV Care, Study Finds.  // Journal of Medical Sciences;2011, Vol. 11 Issue 8, p325 

    No abstract available.

  • Cost-effectiveness of World Health Organization 2010 Guidelines for Prevention of Mother-to-Child HIV Transmission in Zimbabwe. Ciaranello, Andrea L.; Perez, Freddy; Engelsmann, Barbara; Walensky, Rochelle P.; Mushavi, Angela; Rusibamayila, Asinath; Keatinge, Jo; Park, Ji-Eun; Maruva, Matthews; Cerda, Rodrigo; Wood, Robin; Dabis, Francois; Freedberg, Kenneth A. // Clinical Infectious Diseases;Feb2013, Vol. 56 Issue 3, p430 

    We projected outcomes for mothers and infants following World Health Organization–recommended regimens to prevent mother-to-child human immunodeficiency virus (HIV) transmission. Compared with Option A, Option B improves life expectancy and saves money; compared with Option B, lifelong...

  • Health Outcomes and Cost Impact of the New WHO 2013 Guidelines on Prevention of Mother-to-Child Transmission of HIV in Zambia. Ishikawa, Naoko; Shimbo, Takuro; Miyano, Shinsuke; Sikazwe, Izukanji; Mwango, Albert; Ghidinelli, Massimo N.; Syakantu, Gardner // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Background: Countries are currently progressing towards the elimination of new paediatric HIV infections by 2015. WHO published new consolidated guidelines in June 2013, which now recommend either ‘Antiretroviral drugs (ARVs) for women living with HIV during pregnancy and breastfeeding...

  • Prevention of Mother-To-Child Transmission of HIV: Cost-Effectiveness of Antiretroviral Regimens and Feeding Options in Rwanda. Binagwaho, Agnes; Pegurri, Elisabetta; Drobac, Peter C.; Mugwaneza, Placidie; Stulac, Sara N.; Wagner, Claire M.; Karema, Corine; Tsague, Landry // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    Background: Rwanda's National PMTCT program aims to achieve elimination of new HIV infections in children by 2015. In November 2010, Rwanda adopted the WHO 2010 ARV guidelines for PMTCT recommending Option B (HAART) for all HIV-positive pregnant women extended throughout breastfeeding and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics